GLUE•benzinga•
Monte Rosa Therapeutics Says Initial Clinical Data From Phase 1 SAD/MAD Study of VAV1-directed Molecular Glue Degrader (MGD) MRT-6160 Expected In Q1 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 10, 2025 by benzinga